Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Alendronic acid
Drug ID BADD_D00066
Description Alendronic acid is a second generation bisphosphonate that is used for the treatment of some forms of osteoperosis and Paget's disease[FDA Label][A959,A203111]. It functions by preventing resorption of bone[FDA Label][A959].
Indications and Usage Alendronic acid is indicated for the treatment and prevention of osteoporosis in men and postmenopausal women, treatment of glucocorticoid-induced osteoporosis, and Paget's disease of bone[FDA Label][A959,A176750]. However, alendronic acid is not indicated for use in pediatric populations or patients with a creatinine clearance <35mL/min[FDA Label].
Marketing Status approved
ATC Code M05BA04
DrugBank ID DB00630
KEGG ID D07119
MeSH ID D019386
PubChem ID 2088
TTD Drug ID D09KLR
NDC Product Code Not Available
UNII X1J18R4W8P
Synonyms Alendronate | 4-Amino-1-Hydroxybutylidene 1,1-Biphosphonate | Aminohydroxybutane Bisphosphonate | MK-217 | MK 217 | MK217 | Alendronate Monosodium Salt, Trihydrate | Alendronate Sodium | Fosamax
Chemical Information
Molecular Formula C4H13NO7P2
CAS Registry Number 66376-36-1
SMILES C(CC(O)(P(=O)(O)O)P(=O)(O)O)CN
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Delirium19.13.02.0010.000242%
Dementia19.20.02.001; 17.03.01.0010.000484%Not Available
Dementia Alzheimer's type19.20.03.001; 17.03.06.0010.000132%Not Available
Dental caries07.09.01.0010.002413%
Depression19.15.01.0010.005314%
Dermal cyst23.10.02.001; 16.26.02.0010.000242%Not Available
Dermatitis23.03.04.0020.000286%Not Available
Dermatitis allergic23.03.04.003; 10.01.03.0140.000308%Not Available
Dermatitis contact10.01.01.003; 23.03.04.004; 12.03.01.0400.000440%Not Available
Dermatitis exfoliative23.03.07.001; 10.01.01.0040.000044%
Dermatomyositis10.04.04.027; 23.03.02.001; 15.05.01.0020.000044%Not Available
Diabetes mellitus14.06.01.001; 05.06.01.0010.001057%Not Available
Diabetes mellitus inadequate control14.06.01.004; 05.06.01.0040.000220%Not Available
Diabetic neuropathy17.09.04.002; 14.07.04.003; 05.07.04.0030.000154%Not Available
Diabetic retinopathy05.07.01.002; 24.03.07.004; 14.07.01.002; 06.10.02.0020.000044%Not Available
Diaphragmatic hernia22.09.02.001; 07.16.01.0020.000044%Not Available
Diarrhoea07.02.01.001--
Diarrhoea haemorrhagic24.07.02.004; 07.02.01.0020.000044%Not Available
Dilatation atrial02.04.02.0190.000044%Not Available
Dilatation ventricular02.04.02.0260.000066%Not Available
Diplopia17.17.01.005; 06.02.06.0020.000273%Not Available
Discomfort08.01.08.003--Not Available
Disorientation17.02.05.015; 19.13.01.002--Not Available
Diverticulum07.10.01.0010.001431%Not Available
Diverticulum intestinal07.10.01.0020.000440%Not Available
Dizziness02.11.04.006; 24.06.02.007; 17.02.05.0030.002333%
Dizziness postural02.11.04.008; 17.02.05.004; 24.06.02.0080.000088%Not Available
Drooling17.02.05.0050.000110%Not Available
Drug hypersensitivity10.01.01.0010.004764%Not Available
Drug interaction08.06.03.001--Not Available
The 6th Page    First    Pre   6 7 8 9 10    Next   Last    Total 39 Pages